ArticleDermatology and therapy2026
Incidence of Skin Infections in Patients with Atopic Dermatitis Treated with Topical Medications: A Cohort Study Using Japanese Claims Data.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSkin infections are a common concern in the treatment of atopic dermatitis (AD) with topical medications including topical corticosteroids (TCS), tacrolimus, delgocitinib, and difamilast. However, real-world evidence regarding the incidence of these infections across different topical medications remains limited. This study aimed to evaluate patient characteristics and the incidence rates of skin infections associated with topical medications using Japanese claims data.
methodsWe conducted a retrospective cohort study using health insurance claims data from June 2022 to June 2023. Patients with AD were classified into three treatment groups: difamilast, TCS, and non-TCS (tacrolimus and delgocitinib). Incidence rates of skin infections were calculated using the person-year method (1000 person-years). Propensity score matching was used to compare treatment groups.
resultsAmong 107,854 eligible patients, 1,844,45,988, and 8256 received difamilast, TCS, and non-TCS monotherapy, respectively. Before matching, the proportions of female patients were 59.8%, 51.7%, and 66.8% in the difamilast, TCS, and non-TCS groups, and the median ages were 19.0, 13.0, and 38.0 years, respectively. After matching, the incidence rate of skin infections was 362.880/1000 person-years in the difamilast group, compared with 306.336/1000 person-years in the TCS group (risk ratio: 1.185; 95% confidence interval [CI] 0.934, 1.503). Compared with the non-TCS group, the risk ratio was 1.302 (95% CI 1.005, 1.686). No major differences were observed in the incidence of individual skin infections, except for acne. Among patients who received difamilast monotherapy, the incidence rate of skin infections (340.341/1000 person-years; 95% CI 285.209, 406.129) was consistent with the overall patients prescribed difamilast (349.819/1000 person-years; 95% CI 326.257, 375.084).
conclusionsDifamilast demonstrated a comparable safety profile to other topical treatments regarding skin infections in patients with AD. These findings highlight the importance of monitoring infection risk and ensuring appropriate clinical management when prescribing topical medications for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.